Healx key facts
as of Oct 2026- Developer of artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases.
- Healx is valued at approximately $275.9M as of Oct 2026 (last reported valuation).
- It has raised $133.7M; the latest was Later Stage VC ($2.0M) in Jul 2025.
- Notable investors include Global Brain, Intel Capital, Atomico, Balderton Capital, Cambridge Angels — 32 tracked in total.
- Status: Privately Held (backing).
Healx's last reported valuation, Aug 2024. Nothing priced has surfaced since.
- ·The complete investor list: 32 names
- ·Watch Healx: the Monday email on marks, rounds and moves
Healx funding rounds
No funding rounds for Healx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Healx
32+Healx valuation
Healx's last reported valuation was $276 million in Aug 2024. No priced round, secondary trade or fund mark has surfaced since.
Healx investors
32 investors are on record for Healx, including Global Brain, Intel Capital, Atomico and Balderton Capital. By type, the record holds 8 venture capital firms and 1 family office.
About Healx
Developer of artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases. The company offers a combination of frontier machine learning technology and drug discovery expertise, enabling clients to accelerate the development of novel treatments and improve the success rate for addressing the unmet needs of rare disease patients worldwide.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2014
- Employees
- 69
- Website
- healx.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.